Interest of Virtual Reality to Prevent Cancer Patient Anxiety Before Chemotherapy or an Invasive Act

The primary objective of the REV study is to demonstrate the difference of anxiety before and after a virtual reality exposure using the State-Trait Anxiety Inventory (STAI-Y) before patients undergo an oncological procedure (invasive act or chemotherapy (C1D1).

The investigator's REV study aims to recruit 66 patients among three cohorts (22 patients per cohort) in 12 months.

• Breast cancer cohort (patient receiving an adjuvant or neoadjuvant chemotherapy with doxorubicin and cyclophosphamide)
• Head or neck cancer cohort (patient treated by concomitant radiochemotherapy)
• Cancer patient for which an invasive act inducing anxiety is planned (lumbar puncture, ascites puncture, thoracocentesis, myelogram, bone marrow biopsy, urinary catheterization, ..)

The REV study aims to impact Lyon's hospital patients' quality of life and well-being by decreasing their anxiety level during oncological treatments thanks to innovative supportive cares.

Inclusion criteria

For all patients:

• Patient Study Information and written informed consent
• Social Security Affiliation

For breast cancer cohort :

• Adult patient (>18 years)
• Histological or cytological proven breast cancer
• Eligible to an adjuvant or neo-adjuvant IV chemotherapy given every 2 to 3 weeks (with protocol doxorubicin- cyclophosphamide, docetaxel-cyclophosmadide, docetaxel-cyclophosphamide-trastuzumab, docetaxel, carboplatine, trastuzumab, epirubicin-cyclophosphamide, etc)
• Therapeutic strategy validated in multidisciplinary meeting
• First chemotherapy cure (C1D1) not initiated yet
• Patients with a complete healing after resection (for adjuvant chemotherapy)
• Patients that do not report residual pain with an intensity > 4.

For head, neck and bladder cancer cohort :

• Adult patient (>18 years)
• Histological or cytological proven head, neck or bladder cancer
• Patient eligible for an adjuvant or neoadjuvant based on cisplatin.
• Therapeutic strategy validated in multidisciplinary meeting
• First chemotherapy cure (C1D1) not initiated yet
• Patients with a complete healing after resection.
• Patients that do not report residual pain with an intensity > 4.

For invasive act leading to potential anxiety cohort :

• Adult patient (>18 years)
• Histological or cytological proven cancer
• Patient with a planned hospitalization at oncological unit
• Eupneic patient
• Afebrile patient

Patient for whom an invasive act leading to potential anxiety is planned (excluding percutaneous implantable chamber) :

• Puncture
• Deep biopsy
• Sounding
• Endoscopy without general anesthesia
• myelogram

Exclusion criteria

• Patient with a consciousness disturbance or a spatio-temporal disturbance
• Claustrophobic patient
• Patient with a non-stabilized psychiatric pathology
• Patient with seizure crisis background
• Patient with a visual or hearing disturbance that is not compatible with video watching and sound listening
• Patients with out-of range clinical parameters (arterial pressure, cardiac frequency,..)
• Patients with out-of range blood parameters that are not compatible with chemotherapy or an invasive act.
• Patient with a life expectancy below 3 months.
• Impossibility to track and follow patient (any reason)
• Patient deprived of liberty or subjected to guardianship